Download Files:
Products Details
Product Description
– NTQ1062 is a potent and orally active Akt inhibitor with IC50s of 0.4 nM, 6.3 nM and 0.1 nM for Akt1, Akt2 and Akt3, respectively. NTQ1062 induces cell apoptosis and arrests the cell cycle at G0/G1 phase. NTQ1062 exhibits antiproliferation activity against various cancer cells. NTQ1062 exhibits potent antitumor efficacy in LNCap xenograft mouse model[1].
Web ID
– HY-147935
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H31ClN6O2
References
– [1]Ma C, et al. Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. J Med Chem. 2022 Jun 23;65(12):8144-8168.
CAS Number
– 2459489-66-6
Molecular Weight
– 483.01
SMILES
– CC(C)NC[C@H](C1=CC=C(C=C1)Cl)C(N2[C@@]3([H])[C@@](C3)([H])N(C4=C5C(NC=N4)=NC(C[C@H]5C)=O)CC2)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Akt
Isoform
– Akt1;Akt2;Akt3
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
